DEF: DarioHealth Seeks Shareholder Approval for Reverse Stock Split and Major Capital Increase Amid Nasdaq Compliance Concerns

DarioHealth Corp. is calling its annual meeting to vote on critical proposals including a reverse stock split to maintain Nasdaq listing, a significant increase in authorized shares for future capital needs, and amendments to its equity compensation plan.

Summary

• DarioHealth Corp. will hold its Annual Meeting of Stockholders on Wednesday, July 23, 2025, in Caesarea, Israel.
• Key proposals include the re-election of seven directors, ratification of Kesselman & Kesselman (PwC member) as the independent auditor for fiscal year 2025, and amendments to the 2020 Equity Compensation Plan.
• The company is seeking authorization for a reverse stock split at a ratio between 2-for-1 and 25-for-1, to be implemented by September 15, 2025, primarily to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
• DarioHealth received a Nasdaq non-compliance notice on September 16, 2024, and an extension until September 15, 2025, to meet the minimum bid price.
• Shareholders will also vote on increasing the authorized common stock from 160,000,000 to 400,000,000 shares to provide flexibility for future capital raising, strategic transactions, and equity incentives.
• The 2020 Equity Compensation Plan amendment proposes an annual increase of shares available by 6% of fully diluted outstanding common stock from 2026-2030 and the authorization of Restricted Stock Units (RSUs) to attract and retain talent and conserve cash.
• The company reported a net loss of $(42,747,000) for 2024, an improvement from $(59,427,000) in 2023, largely due to an increase in gross profit.
• Total Shareholder Return (TSR) decreased by approximately 54.30% from 2023 to 2024, with a cumulative TSR of $18.37 for the two-year period ended December 31, 2024.
• Executive compensation for the CEO and other Named Executive Officers saw significant increases in 2024 compared to 2023, despite the negative TSR.
• Chen Franco-Yehuda was appointed Chief Financial Officer, Treasurer, and Secretary effective May 15, 2025, replacing Zvi Ben David.
• Steven Nelson was appointed Chief Commercial Officer on June 5, 2024, and Tomer Ben-Kiki was reassigned from COO to Chief Technology Officer on August 7, 2024.

Sentiment

Score: 3

Explanation: The document presents a company facing significant challenges, primarily Nasdaq non-compliance and ongoing net losses, which are strong negative indicators. While management is taking steps to address these (reverse split, increased authorized shares for capital), these actions themselves highlight underlying weaknesses and potential future dilution. The substantial decline in TSR further reinforces a negative sentiment, despite a slight improvement in net loss.

Positives

• The company reported a reduced net loss of $(42,747,000) in 2024, an improvement from $(59,427,000) in 2023, attributed to an increase in gross profit.
• The Board is actively addressing Nasdaq listing compliance by proposing a reverse stock split.
• The proposed amendment to the 2020 Equity Compensation Plan, including the authorization of RSUs and an annual 6% share increase, aims to attract and retain key talent and conserve cash by using equity in lieu of cash payments.
• Strategic hires and reassignments, such as Steven Nelson as Chief Commercial Officer and Tomer Ben-Kiki as Chief Technology Officer, indicate ongoing efforts to strengthen management and business operations.

Negatives

• The company remains unprofitable, reporting a net loss of $(42,747,000) in 2024.
• DarioHealth is not in compliance with Nasdaq's minimum bid price requirement, necessitating a reverse stock split to avoid delisting.
• Total Shareholder Return (TSR) significantly decreased by approximately 54.30% from 2023 to 2024, indicating poor stock performance.
• Cumulative TSR for the two-year period ended December 31, 2024, was a low $18.37, reflecting substantial shareholder value erosion.
• Executive compensation, both total and 'actually paid,' increased substantially from 2023 to 2024, despite the negative TSR and ongoing net losses.

Risks

• Failure to regain Nasdaq compliance: If the reverse stock split does not sufficiently increase the share price or if the company fails to maintain the $1.00 bid price for the required period, its securities may be delisted from The Nasdaq Capital Market.
• Dilution from future share issuances: The proposed increase in authorized common stock from 160 million to 400 million shares, while intended for capital raising and strategic purposes, could lead to significant dilution of existing shareholders' ownership and voting power if a large number of new shares are issued.
• Uncertainty of reverse stock split effectiveness: There is no assurance that the reverse stock split will result in a sustained increase in the per-share market price or that the total market capitalization will not decrease after the split.
• Ongoing net losses and dependence on capital raises: The company has incurred net losses since inception and expects to continue doing so, making it dependent on raising additional funds through debt or equity offerings, which may not always be available on favorable terms.
• Anti-takeover effects: The increased number of authorized but unissued shares could be used by the Board to deter hostile takeover attempts, potentially limiting shareholder influence on corporate control matters.
• Impact of equity compensation on earnings and book value: Future issuance of awards under the 2020 Equity Incentive Plan, especially full-value awards like RSUs, may dilute earnings per share and book value per share.

Future Outlook

The company expects to incur future net losses and states that its transition to profitability is dependent on successful product development, commercialization, and achieving adequate revenues. It intends to fund future operations through cash on hand and additional private and/or public offerings of debt or equity securities. The Board believes increasing authorized shares is necessary to provide flexibility for future capital raises and strategic transactions without delay.

Management Comments

• "Our Board unanimously recommends that the stockholders vote FOR all proposals being put before our stockholders at the Meeting."
• "Our management believes that Proposals 2, 4 and 5 are routine matters for which brokers will have authority to vote your shares at the Meeting if you do not give instruction on how to vote your shares."
• "The primary objective in proposing the Reverse Stock Split is to maintain our listing on the Nasdaq Capital Market, if needed."
• "Reducing the number of outstanding shares of our Common Stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market price of our Common Stock in order to attract new investors and meet the $1.00 per share minimum bid price requirement of Nasdaq."
• "We expect to incur future net losses and our transition to profitability is dependent upon, among other things, the successful development and commercialization of our products and the achievement of a level of revenues adequate to support the cost structure."
• "Our success in achieving our business objectives depend on our ability to raise additional capital in the future, and the Board believes it is in the best interests of the Company and its stockholders to have sufficient flexibility to issue additional shares in the future on a timely basis if such need arises in connection with potential financings or other corporate purposes."
• "If the Authorized Shares Amendment is not approved by our stockholders, the lack of unissued and unreserved authorized shares of common stock to provide future equity incentive opportunities could adversely impact our ability to achieve these goals to retain employees."

Industry Context

DarioHealth operates in the competitive biopharmaceutical and digital health industries, where attracting and retaining highly qualified management and key personnel is crucial. The company's need for a reverse stock split to maintain Nasdaq listing is a common challenge for smaller, growth-stage companies in these sectors that may experience stock price volatility. The emphasis on equity compensation and the need for significant authorized shares for future capital raises are typical for companies in development phases that require substantial funding to support operations and growth initiatives, especially in R&D-intensive fields.

Comparison to Industry Standards

• The company's reported net loss of $(42.7) million in 2024, while an improvement from 2023, indicates continued unprofitability, which is not uncommon for early to mid-stage biopharmaceutical or digital health companies focused on R&D and market penetration. However, sustained losses necessitate ongoing capital raises, which can be dilutive.
• The significant decrease in Total Shareholder Return (TSR) by 54.30% from 2023 to 2024, resulting in a cumulative TSR of $18.37, is a concerning underperformance compared to broader market indices and many established companies in the healthcare technology sector, such as Teladoc Health (TDOC) or Livongo (now part of Teladoc), which, despite their own challenges, have generally demonstrated more stable or positive long-term shareholder returns during periods of growth.
• The necessity of a reverse stock split to maintain Nasdaq listing due to a sub-$1.00 bid price is a red flag often seen in smaller, struggling companies or those with significant market skepticism. While not unique, it signals a challenge in maintaining investor confidence and liquidity, unlike more mature industry players that typically maintain higher stock prices.
• The proposed increase in authorized shares to 400 million, coupled with the ongoing need for capital, suggests a high burn rate and a reliance on equity financing. This contrasts with profitable industry leaders that can fund growth through internal cash generation or less dilutive debt financing.

Management Changes

Corporate Governance

Related Party Transactions

• Lawrence Leisure, a director, has an interest in NearWater Growth, LLC, which provides investment and business consulting services to the company since 2021. NearWater receives a monthly cash retainer of $10,000 (since Feb 24, 2025) and has received approximately 258,000 shares of Common Stock and warrants to purchase up to 125,000 shares for meeting certain milestones (e.g., introducing entities for acquisition/partnership, revenue milestones).

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the proposed increase in authorized shares and future equity capital raises. The reverse stock split aims to prevent delisting, which would negatively impact liquidity and investor confidence, but its effectiveness in sustaining price is uncertain. Negative TSR indicates poor returns for current shareholders.
• **Employees**: The amendment to the equity compensation plan aims to attract and retain key personnel by offering more flexible equity awards (RSUs), potentially benefiting employee morale and alignment with company goals. However, the company's ongoing net losses could create job insecurity.
• **Customers/Suppliers**: No direct impact mentioned, but the company's financial health and ability to raise capital are crucial for continued product development and service delivery, indirectly affecting customer satisfaction and supplier relationships.
• **Creditors**: The company's reliance on future capital raises and ongoing net losses may pose risks to creditors, although the document does not detail debt obligations.

Next Steps

• Hold the Annual Meeting of Stockholders on July 23, 2025, to vote on the proposed resolutions.
• If approved, the Board will determine the exact ratio for the reverse stock split and implement it no later than September 15, 2025, to regain Nasdaq compliance.
• If approved, the company will file the Certificate of Amendment to increase authorized shares as soon as practicable after the meeting.
• The company will continue efforts to develop and commercialize products and achieve revenues to support its cost structure and transition to profitability.
• The company will seek to raise additional funds through private and/or public offerings of debt or equity securities as needed.

Key Dates

Recommendation

Keywords

DarioHealth, SEC Filing, Proxy Statement, Annual Meeting, Reverse Stock Split, Nasdaq Compliance, Authorized Shares Increase, Equity Compensation Plan, Restricted Stock Units, Corporate Governance, Executive Compensation, Financial Performance, Net Loss, Total Shareholder Return, Capital Raise, Healthcare Technology, Digital Health